3-hydroxypyridin-4-one

01/01/2020 - "Survivors treated with IMI and DIBI were found to be free of systemic infection. "
01/01/2019 - "baumannii LAC-4 significantly reduced bacterial burdens in mice, and DIBI also suppressed the spread of the infection to the spleen. "
01/01/2018 - "DIBI also exhibited in vivo anti-infective activity in two distinct MRSA ATCC43300 infection and colonization models in mice. "
01/01/2021 - "DIBI has been shown to enhance antibiotic efficacy for antibiotic-resistant microbes during infection, and it also prevents recovery growth and resistance development during microbe exposure to various antibiotics. "
01/14/2021 - "Peritoneal infection burden was reduced 10-fold by DIBI while DFX and DFP provided no reductions. "

01/14/2021 - "In contrast, DIBI provided therapeutic benefits, consistent with various in vitro and in vivo results from other studies, supporting the potential for its use in treating sepsis."
01/01/2017 - "These findings suggest a potential role for DIBI-B as a candidate drug for sepsis treatment."
01/01/2017 - "Anti-inflammatory effects of a novel iron chelator, DIBI, in experimental sepsis."
05/26/2020 - "These findings support the utility of DIBI as a novel treatment for systemic inflammation, e.g., sepsis."
01/01/2020 - "DIBI has promising potential for sepsis treatment including its use as a sole or an adjunct therapeutic with antibiotics."

05/26/2020 - "These findings support the utility of DIBI as a novel treatment for systemic inflammation, e.g., sepsis."
01/01/2020 - "The novel iron chelator, DIBI, attenuates inflammation and improves outcome in colon ascendens stent peritonitis-induced experimental sepsis."
01/01/2018 - "In a superficial skin wound infection model, topical application of DIBI provided a dose-dependent suppression of infection along with reduced wound inflammation. "
05/26/2020 - "This study investigates the effect of the novel iron chelator, DIBI, in murine models of systemic (hyper-)inflammation: C57BL/6 mice were challenged with toxins from Gram-positive (Staphylococcus aureus: lipoteichoic acid, peptidoglycan) and Gram-negative bacteria (Escherichia coli and Klebsiella pneumoniae: lipopolysaccharide). "
01/14/2021 - "Inflammation in the abdominal sepsis model, assessed by cytokine measurements, indicated exacerbation by DFX and DFO for plasma Interleukin (IL)-6 and reductions to near-control levels for DIBI and DFP. "

01/01/2018 - "Our study has provided evidence that DIBI has anti-inflammatory effects in experimental uveitis. "
01/01/2018 - "As such, we investigated the efficacy of a novel iron chelator, DIBI, as an anti-inflammatory agent in local and systemic models of endotoxin induced uveitis (EIU). "
01/01/2018 - "DIBI, a polymeric hydroxypyridinone iron chelator, reduces ocular inflammation in local and systemic endotoxin-induced uveitis."

01/01/2018 - "DIBI has promise for restricting staphylococcal infection on its own, regardless of the isolate's animal source or antibiotic resistance profile. "